Prognosis by cancer type and incidence of zoledronic acid–related osteonecrosis of the jaw: a single-center retrospective study
- 3 February 2022
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (5) , 4505-4514
Abstract
Purpose Survival time after bisphosphonate use has been increasingly recognized to be associated with the incidence of medication-related osteonecrosis of the jaw (MRONJ); however, this has not been elucidated sufficiently in the literature. This study aimed to clarify the incidence of MRONJ and the corresponding survival rate of patients treated with zoledronic acid (ZA) for each type of cancer and obtain useful information for the oral/dental supportive care of cancer patients. Methods We evaluated 988 patients who were administered ZA at our hospital; among them, 862 patients with metastatic bone tumors or myeloma were included. Results The median survival time (MST) after ZA initiation was 35, 34, 8, 41, 12, and 6 months for patients with breast, prostrate, lung, myeloma, renal, and other cancers, respectively. Patients with cancers that had a short survival time (lung and other cancers [MST = 8 and 6 months, respectively] and cancers with MST < 10 months) did not develop MRONJ; this could be attributed to the shorter duration of ZA administration. The cumulative incidence of MRONJ in breast cancer, prostate cancer, and multiple myeloma was related to the frequency of anti-resorptive drug use and the increased risk over time. In renal cancer, the cumulative incidence of MRONJ increased early, although the MST was 12 months. Conclusion For the dentists in charge of dental management, it is essential to be aware of prognosis-related factors, predict MRONJ risk for each cancer treatment, and use risk prediction in dental management planning, particularly for cancers with non-poor prognosis.Keywords
All Related Versions
This publication has 46 references indexed in Scilit:
- A Retrospective Study Evaluating Frequency and Risk Factors of Osteonecrosis of the Jaw in 576 Cancer Patients Receiving Intravenous BisphosphonatesAmerican Journal of Clinical Oncology, 2012
- Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implicationsOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012
- Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three casesOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2010
- Osteonecrosis of the jaw related to sunitinibOral and Maxillofacial Surgery, 2010
- Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancerBreast Cancer Research and Treatment, 2010
- Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jawScandinavian Journal of Urology and Nephrology, 2009
- Predictors of Survival in Patients With Bone Metastasis of Lung CancerClinical Orthopaedics and Related Research, 2008
- A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myelomaLeukemia, 2007
- Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosisSupportive Care in Cancer, 2006
- Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapyOral Diseases, 2005